Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

In vivo reprogramming of cytotoxic effector CD8+ T cells via fractalkine-conjugated mRNA LNPs

ABSTRACT: Selective in vivo reprogramming of cytotoxic effector CD8+ T (Teff) cells holds tremendous promise as a therapeutic tool but has not yet been accomplished. Here, we demonstrate that fractalkine-conjugated mRNA lipid nanoparticles (mRNA LNPs) can specifically target and deliver mRNA to CX3CR1+ Teff cells in vitro and in vivo. In mice, fractalkine-conjugated LNPs target up to 90% of blood and splenic Teff cells, and delivery of IL-2 encoding mRNA to Teff cells enables robust IL-2 secretion. In rhesus macaques, fractalkine-conjugated mRNA LNPs target up to 100% of peripheral blood Teff cells and delivery of CD62L-mRNA enables transient CD62L expression. Collectively, these data demonstrate the potential of natural receptor ligand-based targeting of mRNA LNPs for effective and efficient transient in vivo modification of Teff cells.

ORGANISM(S): Homo sapiens

PROVIDER: GSE296681 | GEO | 2026/05/21

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Amino acid supplementation enhances in vivo efficacy of lipid nanoparticle-mediated mRNA delivery in preclinical models

Project description:Lipid nanoparticles (LNPs) play a critical role in the delivery of therapeutic mRNA. Despite extensive efforts to optimize lipid formulations for in vivo delivery, efficacy of mRNA by LNPs remains suboptimal in many organs. Here, we demonstrate that LNP delivery efficacy is influenced by cellular metabolism, with the physiologic metabolome imposing constraints on mRNA expression from LNPs. Using an in vitro system, we found that simulated physiologic metabolic conditions led to the downregulation of certain amino acid metabolic programs. Supplementation of an optimized formulation of methionine, arginine, and serine as an amino acid supplement (AAS) which enhanced the uptake of LNPs and the expression of delivered mRNA cargo in epithelial cells in vitro. Co-administration of AAS with LNPs led to a 5- to 20-fold improvement in mRNA expression across various cell types and lipid formulations in vitro . In vivo delivery of mRNA by LNPs co-administered with AAS by multiple routes enhanced in vivo mRNA expression. Delivery of growth hormone encoding mRNA by LNPs with co-administration of AAS improved the liver GH expression and the therapeutic outcomes in a model of inflammatory liver damage. Delivery of gene editing materials by LNP and AAS through intratracheal route increased lung-targeted in vivo gene editing efficiency compared with LNP alone. The addition of an optimized amino acid supplement as a co-delivered agent with LNPs may provide a simple strategy to broadly improve the efficacy of mRNA-based cell and gene therapies.

2026-03-11 | GSE314463 | GEO

Nanoparticle stereochemistry-dependent endocytosis improves in vivo mRNA delivery

Project description:We report the application of single-molecule-based sequencing technology for high-throughput profiling of lipid nanoparticles (LNPs) carrying mRNA in murine liver non parenchymal cells. We report that LNPs containing stereopure 20α-hydroxycholesterol (20α) deliver mRNA to these cells up to three-fold more efficiently than LNPs containing both 20α- and 20ß- hydroxycholesterols (20mix). We show from the sequencing data that 20mix LNPs were sorted into phagocytic pathways, resulting in different functional delivery between stereopure and non-stereopure LNPs. We performed scRNA-seq using the 10X Chromium System, loading ~2,000 cells per condition, and processed the resulting data using Cell Ranger, resulting in an average read depth of ~100,000 reads per cell. These data suggest that stereochemistry-dependent interactions between LNPs and target cells can be exploited to improve mRNA delivery.

2021-08-04 | GSE181333 | GEO

RNA Encoded Peptide Barcodes Enable Efficient in vivo Screening of RNA Delivery Systems

Project description:LNPs have been demonstrated to hold great promise for the clinical advancement of RNA therapeutics. Continued exploration of LNPs for application in new disease areas requires identification and optimisation of leads in a high throughput way. Currently available high throughput in vivo screening platforms are well suited to screen for cellular uptake but less so for functional cargo delivery. We report on a platform which measures functional delivery of LNPs using unique peptide ‘barcodes’. We describe the design and selection of the peptide barcodes and the evaluation of these for the screening of LNPs. We show that proteomic analysis of peptide barcodes correlates with quantification and efficacy of barcoded reporter proteins both in vitro and in vivo and, that the ranking of selected LNPs using peptide barcodes in a pool correlates with ranking using alternative methods in groups of animals treated with individual LNPs. We show that this system is sensitive, selective, and capable of reducing the size of an in vivo study by screening up to 10 unique formulations in a single pool, thus accelerating the discovery of new technologies for mRNA delivery.

2024-10-17 | PXD053797 | Pride

Single cell multiomic readouts reveal that cellular heterogeneity impacts lipid nanoparticle-mediated mRNA delivery

Project description:We report the development of a new multiomic nanoparticle delivery system called Single cEll Nanoparticle Transcriptome-sequencing (SENT-seq), which quantifies how dozens of lipid nanoparticles (LNPs) deliver DNA barcodes and mRNA into cells, subsequent protein production, and the transcriptome, with single cell resolution. We show from the sequencing data that cell heterogeneity influences the efficiency with which LNPs deliver mRNA therapies, and identify cell subtypes that exhibit particularly high or low LNP uptake as well as genes associated with those subtypes. These data suggest that cell subsets have distinct responses to LNPs, and that these differential interactions can affect mRNA therapies.

2023-01-23 | GSE186395 | GEO

Peptide codes for organ-selective mRNA delivery

Project description:Organ-selective delivery of messenger RNA (mRNA) is critical for fulfilling the therapeutic potential of mRNA-based gene and protein replacement technologies. Despite clinical advances in hepatic delivery of mRNA using lipid nanoparticles (LNPs), strategies for extrahepatic organ-selective mRNA delivery remain underexplored. Here, we report a strategy, termed peptide-encoded organ-selective targeting (POST), that allows digital programming of LNPs, through surface engineering with specific amino acid sequences (POST codes), to deliver mRNA to extrahepatic organs after intravenous administration. Our molecular dynamics simulations also suggest the optimized fracture mechanics of peptide-protein assembly as a mechanism underlying sequence-dependent association between POST code and potentially organ-targeting corona proteins. POST codes are also compatible with organ-selective delivery of different ribonucleic acids and multiple gene editing machineries. This “POST code” platform presents a theoretically unlimited modular repertoire for LNP surface engineering for directing organ-tropism, thereby providing opportunities to broaden the scope and versatility of organ-selective mRNA delivery.

2023-07-20 | PXD043932 |

MicroRNA137-loaded lipid nanoparticles regulate synaptic proteins in the prefrontal cortex

Project description:Genome-wide association studies indicate allele variants in MIR137, the host gene of microRNA-137 (miR137), confer an increased risk of schizophrenia (SCZ). Expression of miR137 and its targets, many of which regulate synaptic functioning, are also associated with an increased risk of SCZ. As a result, miR137 represents an attractive target aimed at correcting the molecular basis for synaptic dysfunction in individuals with high genetic risk for SCZ. Advancements in nanotechnology utilize lipid nanoparticles (LNPs) to transport and deliver therapeutic RNA. However, there remains a gap in using LNPs to regulate gene and protein expression in the brain. To study the delivery of nucleic acids by LNPs to the brain, we found that LNPs released miR137 cargo and inhibited synaptic target transcripts in neuronal cultures. Biodistribution of LNPs loaded with firefly luciferase mRNA remained localized to the mouse prefrontal cortex (PFC) injection site without circulating to off-target organs. LNPs encapsulating Cre mRNA preferentially co-expressed in neuronal over microglial or astrocytic cells. Using quantitative proteomics, we found miR137 modulated glutamatergic synaptic protein networks that are commonly dysregulated in SCZ. These studies support engineering the next generation of brain-specific LNPs to deliver personalized RNA therapeutics and improve symptoms of central nervous system disorders.

2023-09-05 | PXD041648 | Pride

Bulk RNA sequencing from liver of mice injected with saline or mRNA-LNPs encoding eGFP, 10ug dose, 24h timepoint, intravenous route.

Project description:This RNA-seq experiment aimed to investigate the delivery of eGFP mRNA-LNPs to the healthy mouse liver, and investigate changes in gene expression within the liver arising from mRNA-LNP administration.

2026-05-20 | GSE331154 | GEO

Ionizable polymeric micelles (IPMs) for efficient siRNA delivery

Project description:Lipid nanoparticles (LNPs) are widely used for nucleic acid delivery but face challenges like limited targeting and accelerated blood clearance. We design three ionizable oligo-mers (IOs) that, with PLA-PEG, form Ionizable Polymeric Micelles (IPMs), a potential siRNA delivery system, which can achieve lysosomal escape. FAPi-modified IPMs (FAPi-IPMs) show higher targeting of activated hepatic stellate cells (HSCs) compared to hepatocytes, silencing both HSP47 and HMGB1, reducing collagen secretion and liv-er inflammation, effectively treating fibrosis. Moreover, IPMs and FAPi-IPMs mitigate accelerated blood clearance and produce fewer PEG antibodies than LNPs. Unlike LNPs, which adsorb apolipoprotein E (ApoE), IPMs and FAPi-IPMs show minimal apolipoprotein adsorption, differentiating their targeting effects from LNPs. In conclu-sion, IPMs represent an alternative nucleic acid delivery system with superior targeting and reduced immune clearance.

2024-11-21 | PXD057444 | Pride

Nanocarrier imaging at single-cell resolution across entire mouse bodies with deep learning

Project description:Efficient and accurate nanocarrier development for targeted drug delivery is hindered by the inability to analyze cell-level biodistribution across intact whole organisms. We introduce SCP-Nano (Single Cell Precision Nanocarrier Identification), a deep learning pipeline designed to quantify the targeting of millions of cells by nanocarriers in whole-mouse bodies imaged at cellular resolution. SCP-Nano revealed the tissue distribution patterns of lipid nanoparticles (LNPs) following different injection routes at doses as low as 0.0005 mg/kg—far below the detection limits of conventional whole-body imaging techniques. Notably, we demonstrated that LNPs carrying SARS-CoV-2 spike mRNA reach heart tissue, leading to changes in the heart's protein composition that suggest immune activation and possible blood vessel damage. Additionally, we showed that SCP-Nano can analyze various types of nanocarriers, including liposomes, polyplexes, DNA origami, and adeno-associated viruses (AAVs). SCP-Nano's high sensitivity enables accurate 3D mapping of nanocarrier distribution throughout mouse bodies, even detecting very low levels in unexpected tissues. SCP-Nano is poised to accelerate the development of precise and safe nanocarrier-based therapeutics.

2024-12-06 | PXD056871 | Pride

Intratumoral administration of lipid nanoparticles carrying mRNA encoding for IL-21, IL-7, and 4-1BBL induces anti-tumor immunity in preclinical tumor models.

Project description:Local delivery of mRNA-based immunotherapy offers a promising avenue for personalized medicine as it enables the production of specific immunomodulatory proteins that can stimulate the immune system to recognize and eliminate cancer cells, showcasing encouraging results in preclinical tumor models while minimizing systemic side effects. Nonetheless, efficient mRNA delivery is challenging due to its rapid degradation by ribonucleases and limited cellular uptake. Here, we developed and employed ionizable lipid nanoparticles (LNPs) to intratumorally deliver an mRNA mixture encoding the cytokines IL-21 and IL-7 and the immunostimulatory molecule 4-1BB ligand (Triplet LNP). The Triplet LNP led to a profound increase in the frequency of tumor-infiltrating granzyme B+ CD8+ T cells and their capacity to secrete IFN-γ, leading to tumor eradication in a CD8+ T cell-dependent manner. Ultimately, the Triplet LNP showed superior therapeutic efficacy to anti-PD1 against the orthotopic triple-negative breast carcinoma model E0771, highlighting the therapeutic potential of the Triplet LNP in multiple murine tumor models.

2024-11-12 | GSE249674 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data